RT Journal Article
T1 Urinary Resveratrol Metabolites Output: Differential Associations with Cardiometabolic Markers and Liver Enzymes in House-Dwelling Subjects Featuring Metabolic Syndrome.
A1 Bullón-Vela, Vanessa
A1 Abete, Itziar
A1 Zulet, Maria Angeles
A1 Xu, Yifan
A1 Martínez-González, Miguel A
A1 Sayón-Orea, Carmen
A1 Ruiz-Canela, Miguel
A1 Toledo, Estefanía
A1 Sánchez, Vicente Martín
A1 Estruch, Ramon
A1 Lamuela-Raventós, Rosa María
A1 Almanza-Aguilera, Enrique
A1 Fitó, Montserrat
A1 Salas-Salvadó, Jordi
A1 Díaz-López, Andrés
A1 Tinahones, Francisco J
A1 Tur, Josep A
A1 Romaguera, Dora
A1 Konieczna, Jadwiga
A1 Pintó, Xavier
A1 Daimiel, Lidia
A1 Rodriguez-Mateos, Ana
A1 Alfredo Martínez, José
K1 antioxidant
K1 inflammation
K1 liver enzymes
K1 metabolic syndrome
K1 non-alcoholic fatty liver disease
K1 resveratrol
AB Metabolic syndrome (MetS) components are strongly associated with increased risk of non-alcoholic fatty liver disease (NAFLD) development. Several studies have supported that resveratrol is associated with anti-inflammatory and antioxidant effects on health status. The main objective of this study was to assess the putative associations between some urinary resveratrol phase II metabolites, cardiometabolic, and liver markers in individuals diagnosed with MetS. In this cross-sectional study, 266 participants from PREDIMED Plus study (PREvención con DIeta MEDiterránea) were divided into tertiles of total urinary resveratrol phase II metabolites (sum of five resveratrol conjugation metabolites). Urinary resveratrol metabolites were analyzed by ultra- performance liquid chromatography coupled to triple quadrupole mass spectrometry (UPLC-Q-q-Q MS), followed by micro-solid phase extraction (µ-SPE) method. Liver function markers were assessed using serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT). Moreover, lipid profile was measured by triglycerides, very-low-density lipoprotein cholesterol (VLDL-c), and total cholesterol/high-density lipoprotein ratio (total cholesterol/HDL). Linear regression adjusted models showed that participants with higher total urine resveratrol concentrations exhibited improved lipid and liver markers compared to the lowest tertile. For lipid determinations: log triglycerides (βT3= -0.15, 95% CI; -0.28, -0.02, p-trend = 0.030), VLDL-c, (βT3= -4.21, 95% CI; -7.97, -0.46, p-trend = 0.039), total cholesterol/HDL ratio Moreover, (βT3= -0.35, 95% CI; -0.66, -0.03, p-trend = 0.241). For liver enzymes: log AST (βT3= -0.12, 95% CI; -0.22, -0.02, p-trend = 0.011, and log GGT (βT3= -0.24, 95% CI; -0.42, -0.06, p-trend = 0.002). However, there is no difference found on glucose variables between groups. To investigate the risk of elevated serum liver markers, flexible regression models indicated that total urine resveratrol metabolites were associated with a lower risk of higher ALT (169.2 to 1314.3 nmol/g creatinine), AST (599.9 to 893.8 nmol/g creatinine), and GGT levels (169.2 to 893.8 nmol/g creatinine). These results suggested that higher urinary concentrations of some resveratrol metabolites might be associated with better lipid profile and hepatic serum enzymes. Moreover, urinary resveratrol excreted showed a reduced odds ratio for higher liver enzymes, which are linked to NAFLD.
YR 2020
FD 2020-09-22
LK http://hdl.handle.net/10668/16308
UL http://hdl.handle.net/10668/16308
LA en
DS RISalud
RD Apr 11, 2025